New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
20/04/2026 – AB Science announced the publication of a new article on the preprint platform medRxiv, evaluating long-term ALS survivors treated with masitinib at 4.5 mg/kg/day in the phase 2b/3 AB10015 study